Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
03/26/2020 03/27/2020 03/30/2020 03/31/2020 04/01/2020 Date
76.92(c) 76(c) 77.8(c) 79.85(c) 78.29 Last
8 109 452 9 969 362 8 569 205 10 365 324 2 867 303 Volume
+3.17% -1.20% +2.37% +2.63% -1.95% Change
More quotes
Financials (USD)
Sales 2020 49 863 M
EBIT 2020 14 853 M
Net income 2020 9 293 M
Debt 2020 19 479 M
Yield 2020 3,74%
Sales 2021 52 648 M
EBIT 2021 16 187 M
Net income 2021 10 642 M
Debt 2021 14 524 M
Yield 2021 3,90%
P/E ratio 2020 20,0x
P/E ratio 2021 17,3x
EV / Sales2020 4,16x
EV / Sales2021 3,85x
Capitalization 188 B
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Sector
Pharmaceuticals
Calendar
04/28Earnings Release
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
03/31NOVARTIS : Sandoz - Novartis donation, Consignment of 30 million hydroxychloroqu..
AQ
03/31NOVARTIS : donates 20,000 doses of hydroxychloroquine for COVID-19 PEP clinical ..
AQ
03/30GLOBAL MARKETS LIVE: Government and central banks urge banks and businesses t..
03/30NOVARTIS : AveXis receives positive CHMP opinion for Zolgensma, the only gene th..
AQ
03/30NOVARTIS : Cosentyx gains positive CHMP opinion for new indication in the axial ..
AQ
03/30NOVARTIS : HHS accepts donations of medicine to Strategic National Stockpile as ..
AQ
03/30NOVARTIS : SAS turns to cargo flights using idled passenger planes
RE
03/30NOVARTIS : Inclisiran Shows Positive Results in Phase III Trials
DJ
03/30NOVARTIS : South Korea to pay 9.1 trillion won cash to families, draw up $5.8 bi..
RE
03/30China unexpectedly cuts reverse repo rate by most in five years to support vi..
RE
03/29NOVARTIS : South Korea to draw up second extra budget, give cash payments to man..
RE
03/26NOVARTIS : ROSEN, A HIGHLY RANKED FIRM, Continues to Investigate Securities Clai..
BU
03/25NOVARTIS : AveXis - Zolgensma data shows rapid, significant, clinically meaningf..
AQ
03/24NOVARTIS : Sandoz acquires US distribution rights to two key hospital injectable..
AQ
03/23NOVARTIS : Sandoz Gets U.S. Distribution Rights for Two Hospital-Injectable Medi..
DJ
More news
News in other languages on NOVARTIS
04:41aNovartis échappe à une sanction dans le dossier des données manipulées
04:26aJefferies senkt Ziel für Novartis auf 95 Franken - 'Buy'
04:19aNovartis kommt bei Datenmanipulation ohne FDA-Sanktionen davon
03:15aAVIS D'ANALYSTES DU JOUR : Safran, FDJ, Novartis, Fresenius, Demant, Vifor Pharm..
03/31Oddo BHF senkt Ziel für Novartis auf 89 Franken - 'Buy'
More news
Analyst Recommendations on NOVARTIS
More recommendations
Stock Trading Strategies
NOVARTIS - 2019
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 100,43  $
Last Close Price 83,01  $
Spread / Highest target 51,1%
Spread / Average Target 21,0%
Spread / Lowest Target -10,9%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-13.11%187 703
JOHNSON & JOHNSON-8.82%345 705
ROCHE HOLDING AG0.02%277 060
MERCK & CO., INC-15.40%195 141
PFIZER, INC.-16.69%181 075
NOVO NORDISK A/S5.82%141 503